Navigation Links
New Chronic Wound Therapy Awarded at Texas' Largest Life Science Event
Date:5/24/2012

SAN ANTONIO, May 24, 2012 /PRNewswire-iReach/ -- An advisory board of industry leaders at the 2012 Texas Life Science Venture Forum in Houston, Texas namedTransCU O2®, a cutting-edge therapy for chronic wounds, one of ten Most Promising Life Science Technologies.  Over 60 companies were invited to present their research and innovations to hundreds of early-stage investors, venture capitalists, and industry leaders.

This award represents another important achievement for Electrochemical Oxygen Concepts (EO2), the maker of the TransCU O2®.  The company has also recently received recognition by the Department of Veterans Affairs.  EO2 CEO Michael Wells says he and his team are honored by the accolades.

"Patients suffering from chronic wounds and their physicians have long been in need of a better therapy to treat their condition," said Wells. "This award from the Texas Life Science Venture Forum further confirms that TransCU O2® is a ground breaking therapy with the ability to improve the health and lives of patients who suffer with difficult-to heal wounds."

The TransCU O2® is a simple-to-use and easy-to-administer therapy that provides a continuous supply of low-dose pure oxygen to treat a variety of wound types such as venous leg ulcers, diabetic foot ulcers, and pressure ulcers.  Oxygen-based therapies have been proven effective in treating chronic wounds but current therapeutic approaches do not allow for 24-hour a day wound treatment.  The TransCU O2® device is lightweight and fully portable.  Its advanced technology allows for the constant monitoring and automatic flow adjustments necessary for the delivery of optimum therapeutic oxygen flow to the wound site.

The Texas Life Science Venture Forum is a joint effort between the Rice Alliance of Technology and Entrepreneurship, BioHouston, and the Texas Healthcare and BioScience Institute and part of the three-day Texas Life Science Conference.  The conference is the most comprehensive showcase of cutting-edge research and innovative entrepreneurs in the state.  Hundreds of investors, entrepreneurs, successful business people and industry leaders attended to learn about, evaluate and network with the presenting companies.

About Electrochemical Oxygen Concepts (EO2™ Concepts):
EO2™ Concepts is a privately held advanced wound care technology company and the developer of an innovative FDA cleared Class III medical device that provides therapy to difficult-to-heal wounds.  The TransCu O2® is an electrochemical low-dose tissue oxygenation and wound monitoring system designed for use with advanced wound dressings as an adjunctive therapy to treat oxygen compromised wounds.  TransCU O2® is a registered trade mark of Electrochemical Oxygen Concepts.  For more information, please visit www.eo2concepts.com.  

Media Contact: Megan Augustine Megan Augustine, 210-296-9520, mg.augustine@gmail.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Electrochemical Oxygen Concepts
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
3. Its Only Heartburn...or is it? Chronic Heartburn a Risk Factor for Precursor to Esophageal Cancer
4. Researchers Report First Successful Treatment of Chronic Traumatic Brain Injury
5. R7128 Receives Fast Track Designation from the FDA for the Treatment of Chronic Hepatitis C Infection
6. New Data Show Improvements in Work Performance in Patients with Chronic Insomnia Treated with AMBIEN CR(R) (zolpidem tartrate extended-release) Tablets CIV
7. Roches Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
8. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
9. Human Genome Sciences Announces Presentation at AASLD of Results of Phase 2b Trial of Albuferon(R) for Chronic Hepatitis C
10. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
11. Synvista Therapeutics Announces Initiation of Phase 2 Study With Alagebrium for Chronic Heart Failure
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016  MedSource announced today that it has ... solution of choice.  This latest decision demonstrates MedSource,s ... their clients by offering a state-of-the-art electronic data ... nowEDC as the EDC platform of choice in ... "nowEDC has long been a preferred EDC platform ...
(Date:6/23/2016)... -- Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that ... PCT (procalcitonin) assay as a dedicated testing solution for ... clearance, Roche is the first IVD company in the ... risk assessment and management. PCT is a ... in blood can aid clinicians in assessing the risk ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... On ... as sponsor of the 2016 Cereal Festival and World’s Longest Breakfast Table in Battle ... honor of the city’s history as home to some of the world’s leading providers ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/26/2016)... Orion, Clarkston, Michigan (PRWEB) , ... June 26, ... ... with respect to fertility once they have been diagnosed with endometriosis. These women ... intercourse but they also require a comprehensive approach that can help for preservation ...
(Date:6/25/2016)... TX (PRWEB) , ... June 25, 2016 , ... Austin ... of the American College of Mohs Surgery and to Dr. Russell Peckham for medical ... and highly effective treatment for skin cancer. The selective fellowship in Mohs Micrographic Surgery ...
(Date:6/25/2016)... ... 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can ... CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn ... X . Simply select a ProHand generator and drag it above media or text ...
Breaking Medicine News(10 mins):